

DAFTAR PUSTAKA

1. Park SH. Diagnosis and treatment of autoimmune hemolytic anemia: classic approach and recent advances. *Blood Res.*2016;51:69-71.
2. Zanella A and Barcellini W. Treatment of autoimmune hemolytic anemias. *Haematol.*2014;99:1547-52.
3. Widayati K, Hariadi, dan Pradjono E. Anemia hemolitik imun. Buku Ajar Ilmu Penyakit Dalam Jilid II Edisi IV. Balai Penerbit FK UI.2007:2607-13.
4. Seve P, Phillippe P, Dufour JF, Brousolle C, and Michel M. Autoimmune hemolytic anemia: classification and therapy approach. *Expert Rv Hematol.*2008;1(2):189-204
5. Zeerleder S. Autoimmune hemolytic anemia- a practical guide to cope with a diagnostic and therapeutic challenge. *Neth J Med.*2011;69:177-182.
6. Gehrs BC and Frienberg RC. Autoimmune hemolytic anemia. *Am J Hematol.*2002;69:258-71
7. Marcus N, Attias D, and Tamary H. Autoimmune hemolytic anemia: current understanding of pathophysiology. *Hematol Educ.*2014;8(1):331-335
8. Barcellini W. New insights in the pathogenesis of autoimmune hemolytic anemia. *Transfus Med Hemother.*2015;42:287-293
9. Lin Xu, Tenglong Z, Zhongming L, Qinchuan L, Zengguang X, and Tao R. Critical role of Th17 cells in development of autoimmune hemolytic anemia. *Exp Hematol.*2012;40:994-1004
10. Andrew M, Omar M, Natasha W, Daniel P, Anne M, and Mark A. Production of the effector cytokine interleukin-17, rather than interferon- γ , is more strongly associated with autoimmune hemolytic anemia. *Haematol.*2012;97(10):1494-1500
11. Zhu S and Qian Y. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. *Clin Sci (Lond).*2012:122-145
12. Thomas K, Estelle B, Mohamed O, and Vijay K. IL-17 and Th17 cells. *Annu Rev Immunol.*2009;27:485-517
13. DeLoughery, TG. Autoimmune hemolytic anemia. *Hematol.*2013;8:2-9

14. Victoria P and Christopher A. The direct antiglobulin test. *Arch Pathol Lab Med.*2017;141:305-309
15. Das SS, Nityanand S, and Chaudhary R. Clinical and serological characterization of autoimmune hemolytic anemia in a tertiary care hospital in North India. *Ann Hematol.* 2009;88:727-732
16. Wikman A, Axedorph U, Gryfelt G, Gustaffson L, Bjorkholm M, and Lundhal J. Characterization of red cell autoantibodies in consecutive DAT-positive patients with relation to in vivo haemolysis. *Ann Hematol.* 2005; 84: 150-158
17. Arena G, Taylor RP, Cascavilla N, and Lindorfer M. Monoclonal antibodies: new therapeutic agents for autoimmune hemolytic anemia? *Endocr Metab Immune Disord. - Drug Targets.*2008;8:62-68.
18. Salama A. Treatment options for primary autoimmune hemolytic anemia: a short comprehensive review. *Transfus Med Hemother.*2015;42:294-301
19. Barcellini W and Fattizzo B. Autoimmune hemolytic anemia - progress in emerging treatment options. *Expert Opin Orphan Drugs.*2018:1-7.
20. Michalak SS, Anna OG, Joanna RM, Edyta WR, Elzbieta N, and Lidia G. Autoimmune hemolytic anemia: current knowledge and perspectives. *Immun Ageing.*2020;17:38
21. Deena K and Ansar A. Regulation of IL-17 in autoimmune diseases by transcriptional factors and microRNAs. *Front Genet.*2015;6:236-245
22. Jay K and Anders L. Interleukin-17 family members and inflammation. *Immunity.*2004;21:467-476
23. Xiaoping Z, Pornpimon A, Chen D, and Hong T. Structure and function of interleukin-17 family cytokines. *Protein Cell.*2011;2(1):26-40
24. Leticia M and Sarah LG. Interleukin 17 family cytokines: signaling mechanisms, biological activities, and therapeutic implications. Harbor Lab Press.2017:1-13
25. Ferreti E, Maurilio P, Claudio D, and Vito P. IL-17 superfamily cytokines modulate normal germinal center B cell migration. *J Leukoc Biol.*2016;100:913-917
26. Aggarwal S and Gurney AL. IL-17: prototype member of an emerging cytokine family. *J Leukoc Biol.*2002;71:1-8

27. Novatchkova M, Leibbrandt A, Werzowa J, Nebuser A, and Eisenhaber F. The STIR-domain superfamily in signal transduction, development and immunity. *Trends Biochem Sci.*2003;28:226-229
28. Ely LK, Fischer S, and Garcia KC. Structural basis of receptor sharing by interleukin 17 cytokines. *Nat Immunol.*2009;10:1245-1251
29. Reiko M and Sarah LG. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. *Immunology.*2010;129:311-321
30. Gaffen S. Structure and signalling in the IL-17 receptor superfamily. *Nat Rev Immunol.*2009;9(8):556
31. Agnes D, Alexandre B, and Jeremy B. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. *Nat Immunol.*2009;10:778-784
32. Tarlinton D. IL-17 drives germinal center B cells? *Nat Immunol.*2008;9(2):124-126
33. Mohan SM, Pierre M, Srinivasa VK, and Jagadeesh B. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. *The Am J Pathol.*2012;181:8-15
34. Lechner, K and Jager U. How to treat autoimmune hemolytic anemia in adults. *Blood.*2010;1:5-10.
35. Zarandona, Manuel J, and Mark H. The role of the coombs test in evaluating hemolysis in adults. *CMAJ.*2006;22:17-31
36. Huh YO, Liu FJ, Rogge K, Chakrabarty L, and Lichtiger B. Positive direct antiglobulin test and high serum immunoglobulin G values. *Am J Clin Pathol.*2008;90:197-200
37. Shi Lin J. Clinical applications of direct antiglobulin test. *Blood Heart Circ.*2018;2(3):1-5
38. Das SS, Chaudhary R, and Khetan D. A comparison of conventional tube test and gel technique in evaluation of direct antiglobulin test. *Hematol.*2007;12:175-178
39. Fabijanka-Mitek J, Poglod R, Adamowicz S, and Lopienska H. Quantitation of red cell-bound IgG by an enzyme-linked antiglobulin test in the patients

- with warm-type autoimmune haemolytic anaemia. *Clin Lab Haematol.*2006;28:241:244
40. Segel GB and Lichtman MA. Direct antiglobulin (“coombs”) test-negative autoimmune hemolytic anemia : a review. *Blood Cells Mol Dis.*2014;1-9
 41. Schroeder HW and Cavacini L. Structure and function of immunoglobulins. *J Allergy Clin Immunol.* 2010;125:41-52
 42. Palmeira PC, Quinello AL, Silveira LCA, and Carneiro S. IgG placental transfer in healthy and pathological pregnancies. *Clin Dev Immunol.* 2012;98:46-56
 43. Amlot PL, Hayes AE, and Gray D. Human immune responses in vivo protein (KLH) and polysaccharide neoantigens; normal subject compared with bone marrow transplant patients on cyclosporines. *Clin Exp Immunol.* 1986;64:125-135
 44. Kawasaki YJ, Suzuki N, Sakai M, Isome R, Nozawa M, Tanji, et al. Evaluation of T helper ½ balance on the basis of IgG subclasses and serum cytokines in children with glomerulonephritis. *Am J Kidney Dis.* 2004;44:42-49
 45. Lechner K and Jager U. How i treat autoimmune hemolytic anemia in adults. *Blood.*2010;1:5-10.
 46. King KE and Ness PM. Treatment of autoimmune hemolytic anemia. *Semin Hematol.*2005;42:131-136
 47. Yu Y, Sun XL, Ma CY, and Guan XZ. Serological characteristics and transfusion efficacy evaluation in 61 cases of autoimmune hemolytic anemia. *Zhonggue Med.*2013;21:1275-1279
 48. Bisharat N, Omari H, Lavi I, and Raz R. Risk of infection and death among post-splenectomy patients. *J Infect.* 2001;43:182-186
 49. Selewski DT, Shah GV, Mody RJ, Rajdev PA, and Mukherji SK. Rituximab (rituxan). *AJNR.*2010;31:1178-79
 50. Birgens H, Frederiksen H, and Hasselbach HC. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune hemolytic anemia. *Br J Haematol.*2013;163:393-399.

51. Berentsen S, Ulvestad E, Gjertsen BT, Hjorth H, and Langholm R. Rituximab for chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. *Blood*.2004;103:2925-8.
52. Hueber W, Patel D, Dryja T, Wright AM, and Koroleva I. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. *Sci Transl Med*.2010;2:52-72
53. Genovese M, Van DB, Roberson SA, and Bojin S. LY2439821, a humanized anti-interleukin 17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. *Arthritis Rheum*.2010;62:929-939
54. Tabarkiewicz J, Pogoda K, Karczmarczyk A, Pozarowski P, and Giannopoulos K. The role of IL-17 and Th17 lymphocytes in autoimmune diseases. *Arch Immunol*.2015;63:435-449
55. Lonngberg AS, Zacharie C, and Skov L. Targeting of interleukin-17 in the treatment of psoriasis. *Clin Cosmet Investig Dermatol*.2014;7:251-259
56. Brembilla NC, Senra L, and Boehncke WH. The IL-17 family of cytokines in psoriasis: IL-17A and beyond. *Front Immunol*.2018;9:1-13
57. Lee J, Lee SY, Kang CM, and Jhun JY. Interleukin-17 enhances germinal center formation and immunoglobulin G1 production in mice. *J Rheum Dis*.2017;24:271-277
58. Rajabto W, Atmakusuma D, dan Setiati S. Profil pasien anemia hemolitik autoimun (AHAI) dan respon pengobatan pasca terapi kortikosteroid di Rumah Sakit Umum Pusat Nasional dr. Cipto Mangunkusumo. *JPDI*. 2016; 3: 206-211
59. Rojas B. Pengaruh transfusi packed red cell leukodepleted terhadap efikasi transfusi dan antibodi imunoglobulin G pada pasien anemia hemolitik autoimun [Tesis]. Padang : Fakultas Kedokteran Universitas Andalas; 2021.
60. Hayat AS, Humaira M, Pathan GN, and Bawany MA. Autoimmune hemolytic anemia (AIHA); a hematological perspective at a tertiary care hospital. *Prof Med J*. 2016;23(11) : 1377-1381
61. Chen C, Wang L, Han B, Qin L, and Ying B. Autoimmune hemolytic anemia in hospitalized patients; 450 patients and their red blood cell transfusions. *Medicine*. 2020;99:1-6.

62. Sudulagunta SR, Kumbhat M, Sodalagunta MB, Nataraju AS, Raja SK, Thejaswi KS, et al. Warm autoimmune hemolytic anemia: clinical profile and management. *J Hematol.*2017;6(1):12-20.
63. Barcellini W, Fattizzo B, Zaninoni A, Radice T, Nichele I, Bona ED, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. *Blood.*2014;124(19):1930-2936.
64. Tranekaer S, Hansen DL, and Frederiksen H. Epidemiology of secondary warm autoimmune haemolytic anaemia—a systematic review and meta-analysis. *J Clin Med.*2021;10: 1244
65. Xing L, Zhao M, Wang Y, Feng Y, Qu Y, Duan N, et al. Characteristics of patients with autoimmune haemolytic anaemia secondary to lymphoproliferative disorder: a single-centre retrospective analysis. *Sci Rep.*2019;9:19716
66. Ridwan M. Korelasi jumlah limfosit B CD20 dengan immunoglobulin antieritrosit pada pasien anemia hemolitik otoimun [Tesis]. Padang : Fakultas Kedokteran Universitas Andalas; 2014.
67. Bencomo AA, Diaz M, Alfonso Y, Valdes O, and Alfonso ME. Quantitation of red cell-bound IgG, IgA, and IgM in patients with autoimmune hemolytic anemia and blood donors by enzyme-linked immunosorbent assay. *Immunohematology.*2003;19:47-53
68. Chaudhary R and Das SS. Significance of quantitation of autoantibodies in the eluate of sensitized red cells in warm autoimmune hemolytic anemia. *Lab Med.* 2009;40: 531-534
69. Rajheswari B. Serological characterization of autoantibodies in autoimmune haemolytic anaemia and its clinical implications [Dissertation]. Chennai : Tamil Nadu Dr M.G.R University; 2016